Dr. Wainberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd
Ste 600
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-6192
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2000 - 2003
- Tel Aviv University SacklerClass of 2000
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- CA State Medical License 2003 - 2025
- NY State Medical License 2001 - 2003
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Start of enrollment: 2007 Dec 01
- Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2009 Sep 01
- Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.Vincent Ribrag, Lara Iglesias, Filippo De Braud, Brigette Ma, Tomoya Yokota
European Journal of Cancer. 2025-02-05 - 1 citationsDKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.Samuel J Klempner, Mohamad Bassam Sonbol, Zev A Wainberg, Hope Elizabeth Uronis, Vi K Chiu
Journal of Clinical Oncology. 2025-01-20 - Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.Sun Young Rha, Yanqiao Zhang, Anneli Elme, Roberto Pazo Cid, Ahmet Alacacioglu
JCO Precision Oncology. 2025-01-01
Journal Articles
- Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric CancerAl Benson, Zev A Wainberg, JAMA Oncology
Lectures
- First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase ...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) can...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
- NALIRIFOX Changes Care in Pancreatic Cancer: Here’s HowFebruary 16th, 2023
- Four-Drug Chemotherapy Regimen Shows Promise for Advanced Pancreatic CancerJanuary 25th, 2023
- NALIRIFOX: A New Reference Standard for Metastatic Pancreatic AdenocarcinomaJanuary 23rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: